N/A N=21 Positive Airway Pressure for the Treatment of Asthma
Asthma · Sleep Apnea
Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=233 Asthma Symptom Management Through Mindfulness Training
Asthma
Primary: Change From Baseline in Asthma Control at 18 Months — 1.27; 1.17 score on a scale
Phase 2 N=18 PEEP as Rescue Therapy for Asthmatics With Elevated BMI
Asthma
Primary: Central and Peripheral Elastance — 391; 461; 587; 334 cmH2O/L
N/A N=7 Imaging Study of the Lungs During an Allergic Asthma Attack
Asthma · Atopy
Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage
Phase 2 N=35 Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.
Asthma
Primary: Late Asthmatic Response (LAR) - Smokers: Absolute Change From Saline in Minimum Forced Expiratory Volume in One Second (FEV1) Between 4-10 Hours (Hrs) After Allergen…
N/A N=2,098 Using Computers to Assist in the Treatment of Asthma in a Pediatric Setting
Asthma
Primary: Diagnosis Rate of Asthma — 54; 87 Participants
Phase 4 N=1,220 Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief
Asthma
Primary: Rate of Asthma Exacerbations Per Year — 0.69; 0.82 Adjusted annualized exacerbations — p=0.048
Early Phase 1 N=9 In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma
Asthma
Primary: Concentration (pg/ml) of CXCL8 Cytokine in Cell Supernatant After Stimulation (IFN/TNF or IL13) and Treatment (VR588, FP or CP) Conditions in ALI Cultured Epithelial…
Phase 2 N=21 Personalized Treatment Algorithms for Difficult-to-treat Asthma
Asthma in Children
Primary: Change in Composite Asthma Severity Index (CASI) — 5; 5; 5 score on a scale — p=0.52
Phase 4 N=103 Individualizing Treatment for Asthma in Primary Care
Asthma · Bronchial Diseases · Respiratory Tract Infections
Primary: Asthma Control as Measured by the Asthma Control Test (ACT) — 18.77; 18.96; 20.45; 20.14 units on a scale
Phase 4 N=10 Aerosolized Beta-Agonist Isomers in Asthma
Asthma
Primary: Change in Maximum Forced Expiratory Volume at One Second (FEV1) — 20; 20; 20; 19 percentage of change
Phase 2 N=49 Oxidative Stress in Asthma
Asthma · Obesity
Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53
N/A N=53 PackHealth: Asthma Engagement Tool
Asthma
Primary: Rate of Asthma Exacerbations — 3.21 events/12 weeks
Early Phase 1 N=39 Defining and Treating Depression-related Asthma
Asthma · Depression · Childhood Asthma
Primary: FEV1 Percent Change Post-ipratropium — 10.8 percent change — p=0.032
N/A N=312 A Patient Advocate to Improve Real-world Asthma Management for Inner City Adults
Asthma · Communication
Primary: Change in Asthma Control at One Year — -0.42; -0.11 units on a scale
N/A N=80 Treatment Phenotypes for Adolescents With Asthma
Asthma in Children · Adherence, Treatment
Primary: Treatment Phenotypes — 7; 2; 10; 5 Participants
N/A N=101,437 Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients
Asthma
Primary: Mean Ratio of Controller Medication to Total Asthma Medication — 0.57; 0.66; 0.66; 0.71 ratio
N/A N=67 Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes
Asthma
Primary: Absolute Change in Morning Peak Flow — -15.7; 8.4; -5.6; -14.4 L/min
Phase 4 N=259 Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma
Asthma
Primary: The Percentage of Participants With Asthma Who Rated the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrated Correct Use of the Inhaler at the…
Phase 2 N=15 A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
Severe, Refractory Asthma · Airway Inflammation · Airflow Obstruction
Primary: 16 Weeks - Juniper Asthma Quality of Life Questionnaire (AQLQ) Score — 4.7; 4.6 units on a scale
N/A N=13 Dietary Supplementation With Soy Isoflavones in Asthma
Asthma
Primary: Exhaled Nitric Oxide — 67.0; 54.8 parts per billion (ppb) — p=<0.03
Phase 2 N=16 The Use of Rosiglitazone to Treat Asthma
Asthma
Primary: Methacholine Responsiveness as Assessed by PC20, — 3.27; 8.71 mg/mL — p=0.048
N/A N=23 Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And Chronic Obstructive Pulmonary Disease (COPD) Patients
Asthma · Chronic Obstructive Pulmonary Disease
Primary: Inhaler Use Correctness — 3.52 correct steps
N/A N=340 Specific Use-result Surveillance of Spiriva Respimat in Asthmatics
Asthma
Primary: Percentage of Patients With Suspected Adverse Drug Reactions (ADRs) — 5.59 Percentage of participants
N/A N=66 Academic Achievement in Children With Asthma
Asthma
Primary: GPA — 2.75; 2.61; 3.25; 2.50 GPA(unweighted)
Phase 4 N=139 Antidepressant Treatment at an Inner City Asthma Clinic
Depression · Asthma
Primary: Asthma Control Questionnaire (ACQ) — 1.15; 1.63; 1.39; 1.23 units on a scale
Phase 4 N=222 An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma
Asthma
Primary: Percentage of Participants From Each Stratum Who Demonstrated Correct Use of the ELLIPTA DPI at Visit 2, Attempt 1 (Day 28) — 92; 93 Percentage of participants
N/A N=1,899 Exacerbation Risk in Asthma
Asthma
Primary: Time to First Severe Exacerbation — 43.75; 49.43 Days — p=0.758
N/A N=31 Effectiveness of the Aeroneb in Acute Severe Asthma
Asthma Exacerbation
Primary: Percentage Change in Mean of Peak Expiratory Flow Rate (PEFR) Percentage of Predicted Baseline at 30 Minutes After the Initial Bronchodilator Treatment — 18.1; 12.9…
N/A N=12,238 Asthma in Families Facing Out-of-pocket Requirements With Deductibles
Asthma
Primary: Change in Percentage of Days Covered for Inhaled Corticosteroids — 51.5; 44.7; 37.0; 29.1 percentage of days — p=0.05